Clinical trials: Bipolar I Disorder, open to volunteers
Schizophrenia / Schizoaffective Disorder, First Episode Psychosis (FEP)
French Minds Cohort: a French Longitudinal and Multimodal Cohort of Patients With Major Mood Disorders, Psychotic Disorders, Autism Spectrum Disorders, and Healthy Controls
The goal of this study is to learn whether people living with severe psychiatric disorders can be grouped into more homogeneous subgroups, across usual diagnostic categories, based on two key dimensions: social withdrawal and…
- Conditions
- Schizophrenia / Schizoaffective Disorder, First Episode Psychosis (FEP), Bipolar Disorder (BD), Major Depressive Disorder (MDD
- Trial name
- FRENCH-MINDS (NCT07881016)
- Testing
- 3T Brain MRI, Biological Sampling, Clinical, Cognitive and Digital Assessments
- Where
- 17 sites in France
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Fondation FondaMental
Bipolar Disorder, Major Depression
NIMH Rhythms and Blues Study: A Prospective Natural History Study of Motor Activity, Mood States, and Bipolar Disorder
Background: Mood disorders, such as bipolar disorder, can have serious effects on a person s life. People with bipolar disorder are more likely to have heart disease and abuse substances.
- Conditions
- Bipolar Disorder, Major Depression, Migraine
- Trial name
- NCT05669703
- Where
- United States
- Volunteers
- 1,260 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Mood Disorders, Anxiety Disorders
Evaluation of Patients With Mood and Anxiety Disorders and Healthy Volunteers
The purpose of this protocol is to allow for the careful screening of patients and healthy volunteers for participation in research protocols in the Experimental Therapeutics and Pathophysiology Lab (ETPB) at the National…
- Conditions
- Mood Disorders, Anxiety Disorders, Healthy Volunteers, Bipolar Disorder
- Trial name
- NCT00024635
- Where
- United States
- Volunteers
- 16,000 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Bipolar Disorder
Three-level Model of DBT-informed Care for Youth With and/or at Familial Risk for Bipolar Disorder (DB3)
This study seeks to bridge the knowledge-to-action gap regarding psychosocial treatment "dosing" for youth with and/or at familial risk for bipolar disorder (BD).
- Trial name
- DB3 (NCT05153369)
- Testing
- Enhanced Care, DBT Skills Training, Dialectical Behavior Therapy Full Intervention
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Centre for Addiction and Mental Health
Bipolar Disorder
Dialectical Behavior Therapy for Youth With and/or at Familial Risk for Bipolar Disorder
Dialectical behavior therapy (DBT) will be conducted over 1 year in youth with and/or at familial risk for bipolar disorder (BD).
- Trial name
- DB1 (NCT05153382)
- Testing
- Dialectical behavioral therapy
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Centre for Addiction and Mental Health
Bipolar Disorder
Pragmatic Patient-oriented Extension Study of Dialectical Behavior Therapy Booster Sessions for Youth With and/or at Familial Risk for Bipolar Disorder
The study intervention is DBT adapted for youth with and/or at familial risk for bipolar disorder. Participants will have completed one full year of DBT in a previous study. This study is examining use of booster sessions.
- Trial name
- DB2 (NCT05627492)
- Testing
- Dialectical behavioral therapy
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia, Bipolar I Disorder
Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
To evaluate the safety and tolerability of iloperidone in adolescent patients with schizophrenia or bipolar I disorder for up to 52 weeks of treatment.
- Trial name
- NCT05648591
- Testing
- Iloperidone
- Where
- 11 sites in United States
- Volunteers
- 100 people
- Sponsor
- Vanda Pharmaceuticals
Schizophrenia, Bipolar Disorder
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
This is a multicenter, global, 26-week, open-label study to assess the safety and tolerability of lumateperone in pediatric patients with schizophrenia, bipolar disorder or autism spectrum disorder.
- Conditions
- Schizophrenia, Bipolar Disorder, Autism Spectrum Disorder
- Trial name
- NCT06229210
- Testing
- Lumateperone
- Where
- 65 sites in United States, Colombia and 1 more
- Volunteers
- 300 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Bipolar Depression
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
This is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients who are experiencing major depressive episodes (MDEs) associated with a primary diagnosis of bipolar I or bipolar II disorder as…
- Trial name
- NCT06372964
- Testing
- Lumateperone
- Where
- 68 sites in United States, Colombia and 2 more
- Volunteers
- 384 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Neurodegenerative Disease, Dementia
Cognition and Affective Research in China
This is a prospective cohort study of patients with cognitive impairment mood disorders and behavioral disorders. Comprehensive baseline and longitudinal follow-up assessments include clinical and epidemiological data, cognitive…
- Conditions
- Neurodegenerative Disease, Dementia, Alzheimer's Disease, Parkinson's Disease
- Trial name
- CARE (NCT07833267)
- Where
- China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Xuanwu Hospital, Beijing
Early Psychosis, Psychosis
State Representation in Early Psychosis 2
This observational study will examine behavioral and electroencephalography measures related to state representation in individuals with early psychosis and healthy control participants.
- Conditions
- Early Psychosis, Psychosis, Schizophrenia, Bipolar Disorder With Psychosis
- Trial name
- STEP2 (NCT07834203)
- Where
- 2 sites in United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Depression / Major Depressive Disorder, Bipolar Disorder (BD)
Identifying Biomarkers of Response to Digital Interventions for Mood Disorders
The proposed study will be a single-arm pragmatic clinical trial examining the feasibility of online CBT within the CAN-BIND sites and the biomarkers of treatment response to online CBT for mood disorders.
- Trial name
- CAN-BIND-iCBT (NCT07783633)
- Testing
- Online Cognitive Behavioural Therapy
- Where
- Canada
- Volunteers
- 200 people
- Sponsor
- Centre for Addiction and Mental Health
Bipolar I Disorder, Schizophrenia
Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects
To evaluate the long-term safety and tolerability of OLZ/SAM in pediatric subjects with schizophrenia or Bipolar I disorder
- Trial name
- NCT04987229
- Testing
- OLZ/SAM
- Where
- 35 sites in United States, Argentina and 3 more
- Volunteers
- 236 people
- Sponsor
- Alkermes, Inc.
Schizophrenia, Bipolar I Disorder
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
To compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs olanzapine
- Trial name
- NCT05303064
- Testing
- OLZ/SAM, Olanzapine
- Where
- 47 sites in United States, Argentina and 3 more
- Volunteers
- 220 people
- Sponsor
- Alkermes, Inc.
Schizophrenia, Schizo-Affective Disorder
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
This is a study of the efficacy and safety of BXCL501 in children and adolescents with acute agitation and either bipolar disorder or schizophrenia.
- Conditions
- Schizophrenia, Schizo-Affective Disorder, Schizophreniform; Schizophrenic, Bipolar Disorder I
- Trial name
- NCT05025605
- Testing
- BXCL501 80 Micrograms, BXCL501 120 Micrograms, BXCL501 60 Micrograms
- Where
- 5 sites in United States
- Volunteers
- 140 people
- Sponsor
- BioXcel Therapeutics Inc
Depression, Bipolar I Disorder
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population and 1.8% of the pediatric population in the United States.
- Trial name
- 3112 Ped BPD (NCT04777357)
- Testing
- Cariprazine
- Where
- 81 sites in United States, Puerto Rico and 1 more
- Volunteers
- 380 people
- Sponsor
- AbbVie
Mood Disorders, Depressive Disorder
An Innovative Master Platform for Clinical Trials in Mood Disorders
Mood disorders such as depression and bipolar disorder affect over 350 million people around the world. While several effective treatments exist, it is often difficult to match the right treatment to an individual person.
- Conditions
- Mood Disorders, Depressive Disorder, Bipolar and Related Disorders
- Trial name
- ENABLE (NCT06408012)
- Where
- 9 sites in Canada
- Volunteers
- 2,200 people, healthy volunteers welcome
- Sponsor
- St. Joseph's Healthcare Hamilton
First-episode Psychosis
Biomarkers Predictive of Thymic Evolution and Therapeutic Response at 2 Years in Patients With a First Psychotic Episode
Psychosis is a severe, common, and disabling psychological disorder. An epidemiological study conducted in England reported an incidence of 34 new cases per 100,000 person-years, with a peak between 16 and 19 years of age.
- Trial name
- PEPAMARKER (NCT05384392)
- Testing
- Recorded interview, Clinical scales, Blood sample
- Where
- 5 sites in France
- Volunteers
- 217 people
- Sponsor
- University Hospital, Brest
Bipolar Disorder (BD), Bipolar Disorder I or II
FOCUS Bipolar: Families Opening Conversations for Understanding Signs
Bipolar disorder often runs in families, but early symptoms in youth can go unrecognized for years. This project evaluates a structured, family-centered approach to informed screening for youth ages 7-21 who have a biological…
- Conditions
- Bipolar Disorder (BD), Bipolar Disorder I or II, Bipolar Disorder Family Members, Screening Tool
- Trial name
- FOCUS Bipolar (NCT07622927)
- Testing
- Co-design Workshop (Observational Procedure), Alpha Testing (Observational Procedure), Beta Testing (Observational Procedure)
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Bipolar Disorder, Schizophrenia
Immuno-Genetic, Inflammation, Retro-Virus, Environment
Immunology combined to neurobiology now offer prominent tools to yield biomarkers, so far missing in psychiatry, and to design innovative treatment approaches based on the discovery of new molecular and cellular targets.
- Trial name
- I-Give (NCT02878408)
- Testing
- Blood sampling
- Where
- 6 sites in France
- Volunteers
- 1,100 people, healthy volunteers welcome
- Sponsor
- Pr. Marion Leboyer